(Health Korea News / Lee Chang-yong) It was found that the combination therapy of Yuhan Corporation’s non-small cell lung cancer treatment ‘Leclaza (ingredient name: Lazertinib)’ and Janssen (J&J)’s non-small cell lung cancer treatment ‘Librivant (ingredient name: amivantamab)’ showed a higher survival rate than AstraZeneca’s ‘Tagrisso (ingredient name: osimertinib)’ monotherapy.
J&J announced on the 8th (local time) at the World Conference On Lung Cancer 20204 (WCLC 2024) held in San Diego, USA that the ‘lazertinib and amivantamab’ combination therapy (MARIPOSA) showed a higher survival rate than osimertinib monotherapy in a phase 3 clinical trial conducted on adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation.
This study was conducted over 3 years (median follow-up period of 31.1 months) in 1,074 patients with EGFR-mutated adult non-small cell lung cancer (NSCLC). Overall survival (OS), overall response rate (ORR), duration of response (DOR), second progression-free survival (PFS2), and intracranial PFS were evaluated.
The study results showed that the survival rate of patients who received the ‘lazertinib and amivantamab’ combination therapy was 61%, and the survival rate of patients who received osimertinib treatment was 53%, showing that the survival rate of patients treated with the ‘lazertinib and amivantamab’ combination therapy was 8% higher.
The PFS in the brain was 38% for ‘lazertinib and amivantamab’, which was twice that of osimertinib at 18%. The rate of patients treated with the ‘lazertinib and amivantamab’ combination therapy continuing treatment after 3 years was 40%, which was higher than that of osimertinib at 29%. It is interpreted that the lazertinib and amivantamab combination therapy helped maintain treatment longer than osimertinib.
The proportion of patients who did not start a new treatment was 45% for the ‘lazertinib·amivantamab’ combination therapy, which was higher than 32% for osimertinib. This shows that patients treated with the ‘lazertinib·amivantamab’ combination therapy did not start a new treatment and maintained the same treatment.
The survival rate without progression of cancer after the first follow-up treatment (the first additional treatment received when cancer progresses or relapses) was 57% for ‘lazertinib/amivantamab’ and 49% for osimertinib.
“At J&J, we are committed to advancing the treatment of lung cancer by delivering precision therapies that can improve outcomes from the earliest stages of treatment,” a J&J official said. “The long-term follow-up results from this study add to the strong evidence supporting the combination of lazertinib and amivantamab as a first-line treatment for patients with EGFR-mutated non-small cell lung cancer.”
Previously, on the 19th of last month, J&J received approval from the FDA for the combination therapy of ‘Leclaza’ and Librivant (ingredient name: amivantamab) as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation.
The European Commission (EC) also approved the ‘Librivant + chemotherapy’ combination therapy on the 27th of last month (local time). It is used as a treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20INS mutations who previously received TKI treatment.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
